High Potency APIs Market By Product Type (Innovative High-Potency API, Generic High-Potency API), By Application (Oncology, Hormonal Imbalance, Glaucoma, Others), By Type of Synthesis (Synthetic, Biotech): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global high potency APIs market was valued at $19,693.65 million in 2021, and is projected to reach $41,373.34 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
High potency APIs are the substances that elicit a biological response even at very low doses. Cytotoxic substances and sex hormones like oestrogen are the common examples of HPAPIs which are highly selective in nature and show response at low doses. Moreover, the API development sector including the development of the HPAPIs, is the fastest expanding area of the pharmaceutical industry due to the development of the highly potent drugs such as fentanyl, alprazolam, risperidone, bumetanide, bisoprolol that evokes response at low concentrations and are into the market for the treatment of various ailments. In addition, more than 1,000 highly potent small molecules are under development that have their applications in the treatment of diseases like cancer, diabetes, glaucoma, and others.
According to the National Glaucoma Research, more than three million Americans have glaucoma, and 2.7 million of these patients are aged 40 and older and are affected by its most common form, open-angle glaucoma. Also, in 2020, about 80 million people have glaucoma globally, and this number is expected to increase to over 111 million by 2040. This rise in the number of the glaucoma patients, along with the prevalence of other multi-genetic disorders such as cancer, diabetes, and others around the globe, propel the growth of the high potency APIs market.
Furthermore, the key market players in the market are focusing on the emerging economies such as India, China and the Middle East Asia for investment and expansion of their business. The rise in the population in this region, along with prevalence of the excessive raw materials for the manufacturing and funding offered by the government are the factors driving the growth of the market in this region. In addition, NCBI states that the primary angle closure glaucoma (PACG) is higher in Asians than Europeans and Africans, with over 80% of the total cases globally, which highlights the investment opportunities for the key market players in the high potency APIs market during the forecast period.
In addition, there is an increase in the demand for oncology drugs due to the prevalence of the cancer cases around the globe. Also, advancements in HPAPI manufacturing technologies along with the rise in the number of contract manufacturing organization (CMOs) and contract development and manufacturing organization (CDMOs) are the factors driving the growth of the market. On the other hand, the patent expiry and launch of the generic versions of the highly potent APIs are projected to provide lucrative opportunity for the pharmaceutical companies to enhance product portfolio and expand their business.
However, the market is expected to be significantly constrained in the near future due to the high risk of cross-contamination and high development cost associated with the manufacturing process. The market is capital intensive and requires skilled technical human capital. This is projected to be a major barrier for new entrants entering the market.
The high potency APIs market is segmented on the basis of product type, application, type of synthesis and region. By product type, it is divided into innovative high-potency API and generic high-potency API. On the basis of application, the market is segmented into oncology, hormonal imbalance, glaucoma, and others. According to the type of synthesis, the market is segmented into synthetic and biotech. The biotech is further divided into merchant and captive. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in this report include Abbvie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and others.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the high potency apis market analysis from 2021 to 2031 to identify the prevailing high potency apis market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the high potency apis market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global high potency apis market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
Oncology
Hormonal Imbalance
Glaucoma
Others
By Type of Synthesis
Synthetic
Biotech
Type
Merchant
Captive
By Product Type
Innovative High-Potency API
Generic High-Potency API
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
AbbVie Inc.
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche
Novartis International AG
Pfizer, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook